Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs
|
Ryan McBride |
11/11/09 |
Boston
|
|
Build it Boldly, and Pharma Will Come—and More Wisdom from Boston’s Biotech and Pharma Elite at Xconomy Forum
|
Ryan McBride |
11/05/09 |
Boston
|
|
Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
11/04/09 |
Boston
|
|
Student Dissertation Launches San Diego Life Sciences Tools Company, Sirigen
|
Denise Gellene |
11/04/09 |
San Diego
|
|
Idenix Shares Drop as Novartis Walks Away From Hepatitis C Drug
|
Luke Timmerman |
10/30/09 |
Boston
|
|
Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/09/09 |
Boston
|
|
Ironwood Recruits Genentech, Facebook Star as Company Knocks on Wall Street Doors
|
Luke Timmerman |
10/05/09 |
Boston
|
|
Botox’s Singh Moves on to San Diego’s Transdel, Developer of Pain Reliever to Rival Advil
|
Luke Timmerman |
09/28/09 |
San Diego
|
|
Autism Gets a Boost: Seaside Therapeutics Raises $30M To Develop First Drugs That Might Work
|
Luke Timmerman |
09/17/09 |
Boston
|
|
Ascent Therapeutics’ Blood Cancer Drug Could Rival Genzyme’s Mozobil
|
Ryan McBride |
09/16/09 |
Boston
|
|
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug
|
Luke Timmerman |
09/10/09 |
San Diego
|
|
Orexigen Aims to Redefine Obesity, as Amgen Vet Revamps Company to Compete
|
Luke Timmerman |
09/02/09 |
San Diego
|
|
Intellikine, Stocked With Cash, Pushes Portfolio of Drugs Against Biology’s Hot Targets
|
Luke Timmerman |
08/18/09 |
San Diego
|
|
Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed
|
Luke Timmerman |
08/12/09 |
Seattle
|
|
Vertex Scores $105M For Asian Telaprevir Rights, Avila Avails Itself of $30M, IBM Picks Up Ounce Labs, & More Boston-Area Deals News
|
Rebecca Zacks |
07/31/09 |
Boston
|
|
Forma and Novartis Form Cancer Drug Collaboration
|
Ryan McBride |
07/29/09 |
Boston
|
|
$8M More for Acquia, Novartis-Alnylam Collaboration Continues, Virtualization Firm Akiba Acquires $6.53M, & More Boston-Area Deals News
|
Rebecca Zacks |
07/24/09 |
Boston
|
|
Novartis Extends Alnylam Deal
|
Ryan McBride |
07/17/09 |
Boston
|
|
Intellikine Attracts Novartis, Biogen, and Others for $51M Second Round
|
Ryan McBride |
07/09/09 |
San Diego
|
|
Amgen’s Dmab Works in Cancer Trial
|
Luke Timmerman |
07/07/09 |
Seattle
|
|
Immuneering, Led by Young CEO and Mentor, Aims to Pick Which Cancer Drugs Should Work
|
Luke Timmerman |
07/07/09 |
Boston
|
|
Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga
|
Ryan McBride |
07/06/09 |
Boston
|
|
Intellikine, Chasing Hot Cancer Drug Target, Raises Big Venture Round
|
Luke Timmerman |
07/02/09 |
San Diego
|
|
Balancing Computer Security and Innovation—A Talk with RSA’s Art Coviello
|
Wade Roush |
06/29/09 |
Boston
|
|
Data Domain Fight Continues, Adimab Adds Merck and Roche as Partners, BigBelly Solar Gets Dirty With Waste Management, & More Boston-Area Deals News
|
Eric Hal Schwartz |
06/22/09 |
Boston
|
|
Inside a Life Sciences Industry Confab: Notes from Convergence
|
Ryan McBride |
06/17/09 |
Boston
|
|
Johnson & Johnson, TB Alliance Form Partnership to Push New TB Drug Through Clinic
|
Luke Timmerman |
06/17/09 |
Seattle
|
|
Merck and Roche Back Adimab, Viral Contamination Closes Genzyme Plant, Interlace Ties on $20.5M, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
06/17/09 |
Boston
|
|
MDRNA Pays Off $5.5M Debt
|
Luke Timmerman |
06/16/09 |
Seattle
|
|
Page 1 of
4 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
